Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

Core Insights - Cytokinetics is hosting the Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) to foster collaboration and innovation in muscle biology research [1][2] - The company is focused on developing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases related to cardiac muscle performance [3] Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in cardiovascular treatments, particularly targeting muscle performance [3] - The company is preparing for regulatory submissions for aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Other ongoing clinical trials for aficamten include MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, and FOREST-HCM, focusing on various patient populations with hypertrophic cardiomyopathy [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure and CK-586 and CK-136 for different types of heart failure [3] Event Details - The CLIMB symposium aims to bring together scientists and researchers to share innovative research and promote interdisciplinary dialogue in muscle biology [2] - The event features expert speakers and poster presentations, enhancing networking opportunities within the muscle biology community [2][4]